Achieve Life Sciences (ACHV) Projected to Post Quarterly Earnings on Thursday

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) is projected to release its earnings data before the market opens on Thursday, March 27th. Analysts expect Achieve Life Sciences to post earnings of ($0.29) per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last released its quarterly earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.06). On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Achieve Life Sciences Trading Up 2.2 %

Shares of Achieve Life Sciences stock traded up $0.06 during mid-day trading on Friday, hitting $2.81. 207,633 shares of the stock were exchanged, compared to its average volume of 170,817. The stock has a market capitalization of $97.46 million, a price-to-earnings ratio of -2.49 and a beta of 1.67. Achieve Life Sciences has a twelve month low of $2.51 and a twelve month high of $5.59. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31. The company has a 50-day simple moving average of $3.09 and a 200 day simple moving average of $3.95.

Remove Ads

Insider Transactions at Achieve Life Sciences

In related news, CFO Mark K. Oki acquired 10,000 shares of the business's stock in a transaction dated Monday, March 17th. The shares were acquired at an average cost of $2.89 per share, for a total transaction of $28,900.00. Following the acquisition, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $28,900. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 2.00% of the company's stock.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.